Yes, breast cancer can spread to the lungs, and it is one of the most common sites where breast cancer metastasizes. The lungs, along with bones, liver, and brain, are the organs breast cancer cells most frequently travel to. In autopsy studies of patients with metastatic breast cancer, 57 to 77% had lung involvement. In living patients being treated for metastatic disease, roughly 23% have detectable lung metastases, with about 6% having spread confined only to the lungs.
How Breast Cancer Reaches the Lungs
Breast cancer cells don’t just grow randomly in distant organs. They follow chemical signals. Lung tissue produces high levels of a signaling protein that acts like a homing beacon for breast cancer cells equipped with the matching receptor. This same protein is also abundant in bone, liver, and lymph nodes, which explains why breast cancer tends to land in these specific locations rather than spreading everywhere at once.
Once cancer cells arrive in the lungs through the bloodstream, they need to establish themselves in unfamiliar tissue. Specialized proteins in the lung’s structural framework help cancer cells anchor and survive during this early colonization phase. Not every cancer cell that reaches the lungs succeeds. Many are destroyed by the immune system or fail to establish a blood supply. But the cells that do take hold can grow into new tumors over weeks, months, or even years after the original breast cancer diagnosis.
Some Subtypes Spread to Lungs More Often
Your breast cancer subtype influences where metastasis is most likely to occur. Triple-negative breast cancer, which lacks hormone receptors and the HER2 protein, shows a particular tendency toward the lungs and brain. In one study, 10.5% of triple-negative patients developed lung metastases, compared to just 2.8% of HER2-positive patients and about 7% of other HER2-negative subtypes. This difference matters because triple-negative breast cancer also has fewer targeted treatment options, making early detection of spread especially important.
Symptoms of Lung Metastasis
Small lung metastases often cause no symptoms at all and are discovered on routine imaging during follow-up care. As tumors grow or multiply, the most common symptoms include shortness of breath, a persistent cough that doesn’t resolve, chest pain, and unexplained fatigue. These symptoms can develop gradually, making them easy to dismiss as a cold or seasonal allergy.
One complication that frequently brings noticeable symptoms is pleural effusion, a buildup of fluid between the lung and the chest wall. This fluid compresses the lung and can cause sudden or worsening breathlessness. Pleural effusion is sometimes the first sign that breast cancer has reached the chest. If fluid accumulates significantly, it can be drained through a needle procedure that provides rapid relief. For fluid that keeps returning, doctors may seal the space between the lung and chest wall using a substance like talc, or place a small tunneled catheter that allows ongoing drainage at home.
How Lung Metastasis Is Detected
CT scans are the primary tool for evaluating the chest when lung metastasis is suspected. On imaging, lung metastases from breast cancer can appear as single or multiple rounded nodules of varying size, areas of consolidation in the lung tissue, or a pattern called lymphangitic carcinomatosis where cancer spreads along the lung’s lymphatic channels. PET scans and MRI can sometimes detect lesions that CT misses.
One important diagnostic challenge is distinguishing metastatic breast cancer in the lung from a new, separate lung cancer. Both cancers can look similar on imaging, and they share certain lab markers. When a biopsy is taken, pathologists use a combination of protein markers to tell them apart. Breast cancer cells typically test positive for estrogen receptor and proteins like GATA-3 and mammaglobin, while primary lung cancers test positive for different markers like TTF-1 and Napsin A. Getting this distinction right is critical because the treatment for metastatic breast cancer in the lung is completely different from treatment for a primary lung cancer.
Treatment for Breast Cancer in the Lungs
When breast cancer spreads to the lungs, treatment is systemic, meaning it targets cancer throughout the body rather than focusing only on the lung tumors. The specific approach depends heavily on your breast cancer subtype.
For hormone receptor-positive breast cancer, which is the most common type, first-line treatment typically combines hormone-blocking therapy with a drug that inhibits cancer cell division (a CDK4/6 inhibitor). This combination can control the disease for months or years in many patients. If that stops working, second-line options include different hormone therapy combinations or adding drugs that target specific growth pathways the cancer may be using to resist treatment.
HER2-positive breast cancer that has spread to the lungs is treated with targeted antibodies combined with chemotherapy. These targeted treatments bind directly to the HER2 protein on cancer cells. Newer antibody-drug conjugates deliver chemotherapy directly into HER2-positive cells, reducing damage to healthy tissue. For triple-negative breast cancer, single-agent chemotherapy is the standard first approach, sometimes combined with immunotherapy if the cancer expresses certain immune markers.
Regardless of subtype, doctors generally prefer single-drug chemotherapy over combination regimens unless the disease is immediately life-threatening. Single agents tend to cause fewer side effects while providing similar benefit, preserving quality of life for what is typically a long-term treatment course.
Survival and Monitoring
Stage IV breast cancer, which includes any distant spread such as to the lungs, has a five-year relative survival rate of about 31%. That number reflects cases diagnosed between 2013 and 2020 and varies significantly based on subtype, the extent of spread, and how well the cancer responds to treatment. Patients whose metastasis is confined to the lungs generally fare better than those with cancer in multiple organ systems.
Once lung metastasis is confirmed, restaging happens every three to six months, or sooner if symptoms change. This typically involves CT scans, blood work, and sometimes PET scans. Blood tests for tumor markers like CA15-3 or CA27.29 can help track whether treatment is working, though doctors interpret these alongside imaging results rather than relying on them alone. If scans show the cancer is stable or shrinking, you stay on your current treatment. If the cancer grows, your oncologist will shift to the next line of therapy.